查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496766

基底细胞癌治疗市场：按类型、途径、临床品种、最终用户划分 - 全球预测 2024-2030

Basal Cell Carcinoma Treatment Market by Type (Drug Therapy, Radiation Therapy, Surgery), Route of Administration (Oral, Parenteral), Clinical Variant, End-Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

基底细胞癌治疗市场规模预计2023年为64.7亿美元，2024年达69.4亿美元，预计2030年将达到108.7亿美元，复合年增长率为7.67%。

基底细胞癌（BCC）治疗是指用于切除或破坏基底细胞癌的各种医疗介入措施。这种癌症生长缓慢，主要发生在经常暴露在阳光下的皮肤区域，例如脸部、耳朵和头皮。治疗方法取决于肿瘤的大小、位置和严重程度，可能包括手术方法，如切除和显微组织学 (MoHS)、局部药物、放射线治疗和晚期病例的标靶药物治疗。由于紫外线 (UV) 暴露的增加和人口老化，全球皮肤癌（尤其是基底细胞癌）病例数量的增加，极大地推动了对快速有效治疗的需求。主要由于公共卫生宣传活动和媒体报告的增加，人们对皮肤癌症状、风险和预防措施的治疗认识不断提高，导致越来越多的人寻求基底细胞癌的早期诊断和治疗。然而，某些 BSS 治疗，例如莫氏手术，需要高度的专业知识和精确度，而缺乏熟练的专业人员对 BCC 治疗的采用构成了障碍。此外，副作用以及治疗不准确和无效的可能性可能会阻碍患者寻求 BCC 治疗。领先者和研究机构对基底细胞癌的遗传和分子机制正在进行的研究正在导致更有针对性和个性化的治疗方法的开发，这些治疗方法可能会提高治疗效果并减少副作用，这为治疗基底细胞癌症开闢了机会。扩大远距远端医疗服务并整合人工智慧以提供更好的诊断工具和治疗计划将使专家护理更接近家庭，尤其是在服务不足的社区。

主要市场统计
基准年[2023] 64.7亿美元
预测年份 [2024] 69.4亿美元
预测年份 [2030] 108.7亿美元
复合年增长率（%） 7.67%

区域洞察

以美国和加拿大为中心的美洲地区是一个高度发展的市场，拥有强大的医疗基础设施和对癌症研究的大量投资。这些地区的消费者受益于早期筛检计划，有助于提高意识和早期诊断。患者更喜欢创新的治疗方法，例如标靶治疗和先进的非侵入性技术。保险范围极大影响客户的购买行为，大多数患者选择卫生当局核准的治疗方法。在欧盟 (EU)，医疗保健系统涵盖广泛的领域，影响治疗的获得和消费者的购买决策。重点放在成本效率和实证治疗。最近的欧盟范围内的倡议旨在协调癌症治疗通讯协定并增加获得优质治疗选择的机会。关于 BCC 治疗的核准、安全性和有效性的严格法规创建了标准化框架，并促进了先进和安全治疗方法的发展。由于人们对皮肤癌的认识不断提高以及政府对扩大医疗保健解决方案的支持，亚太地区 BCC 治疗市场的前景不断变化。中国、日本、印度、韩国、新加坡和澳洲正在大力投资肿瘤学研究和医疗基础设施，重点是开发具有成本效益的治疗解决方案。数位医疗措施和远端医疗的普及在改善 BCC 治疗的可近性方面发挥着重要作用。

FPNV定位矩阵

FPNV 定位矩阵对于评估基底细胞癌治疗市场供应商的市场定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对基底细胞癌治疗市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该行业竞争性质的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在基底细胞癌治疗市场中的地位进行全面评估将有助于公司做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 基底细胞癌的全球盛行率
      • 世界各地对皮肤癌早期诊断和治疗的认识正在增强
    • 抑制因素
      • 基底细胞癌治疗费用高
    • 机会
      • BCC 治疗的进展和改进
      • 远端医疗和远距皮肤病学的新兴趋势
    • 任务
      • 对严格监管核准的担忧
  • 市场区隔分析
    • 治疗类型：高效药物治疗和手术介入以彻底扩大BCC
    • 给药途径：肠外给药起效迅速，适合治疗严重的BCC病例。
    • 临床变异：我们专注于改进和提供针对 BCC 的先进治疗方法，以控制硬化性和表面扩散性 BCC 的侵袭性。
    • 最终用户：政府对医院和诊所设施的扩建和现代化的支持。
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章基底细胞癌治疗市场：依类型

  • 药物治疗
  • 放射治疗
  • 外科手术

第七章基底细胞癌治疗市场：依给药途径

  • 口服
  • 胃肠外的

第八章依临床类型分類的基底细胞癌治疗市场

  • 结节性基底细胞癌
  • 色素性基底细胞癌
  • 硬化性基底细胞癌
  • 表浅扩散性基底细胞癌

第九章基底细胞癌治疗市场：依最终用户分类

  • 居家护理
  • 医院/诊所
  • 专业中心

第10章美洲基底细胞癌治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区基底细胞癌治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲基底细胞癌治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Elekta 推出 Evo，一款革命性的自我调整CT 直线加速器，可增强癌症治疗
    • Medicus Pharma Co., Ltd.透过策略性收购和加强监管策略来推进基底细胞癌治疗
    • Medicus Pharma Ltd. 在非侵入性基底细胞癌治疗方面的创新进展、监管发展和临床研究更新。
    • FDA核准的创新设备增强了基层医疗机构中皮肤癌的早期检测
    • 基底细胞癌非手术治疗方法 VP-315 2 期试验的最终入组和剂量
    • Medison Pharma 与 Regeneron 之间的策略联盟增强了 Ribtayo 在癌症治疗中的全球使用
    • 艾伯维 (AbbVie) 与 Umoja Biopharma 建立策略联盟，透过创新嵌合体抗原受体 (CAR) T 细胞疗法推进肿瘤治疗
    • Medicus Pharma 创新 2 期临床试验以非侵入性治疗基底细胞癌为目标
    • 百时美施贵宝透过策略性收购加强肿瘤产品组合
    • 欧盟核准Ribtayo 治疗进行性肺癌扩大了治疗可能性
  • 战略分析和建议
    • 博士健康公司有限公司
    • 百时美施贵宝公司
    • 再生元製药公司
    • F.霍夫曼拉罗氏股份公司
    • 太阳製药工业有限公司

第14章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-5C6F41F5B0CA

[193 Pages Report] The Basal Cell Carcinoma Treatment Market size was estimated at USD 6.47 billion in 2023 and expected to reach USD 6.94 billion in 2024, at a CAGR 7.67% to reach USD 10.87 billion by 2030.

Basal cell carcinoma (BCC) treatment refers to the various medical interventions used to remove or destroy basal cell carcinomas. This cancer grows slowly and majorly affects areas of the skin that experience frequent sun exposure, such as the face, ears, and scalp. Treatments vary depending on the size, location, and severity of the tumor and include surgical methods such as excision and micrographically oriented histographic (Mohs) surgery, topical medications, radiation therapy, and, in advanced cases, targeted drug therapies. The rising number of skin cancer cases globally, particularly basal cell carcinomas, driven by increased ultraviolet (UV) exposure and aging populations, significantly propels the need for quick and effective treatments. Growing awareness about skin cancer symptoms, risks, and preventive measures, largely due to public health campaigns and increased media coverage, has led more individuals to seek early diagnosis and treatment for BCC. However, certain BSS treatments, such as Mohs surgery, require high levels of expertise and precision, and the lack of skilled professionals poses hurdles to the adoption of BCC treatments. Moreover, the possibility of side effects and inaccurate and ineffective treatment can dissuade patients from seeking BCC treatments. Continued research by key players and research institutions into the genetic and molecular mechanisms underlying basal cell carcinomas opens opportunities for the development of more targeted, personalized therapies that could improve treatment efficacy and reduce side effects. Expanding telemedicine services and integrating artificial intelligence for better diagnostic tools and treatment planning can make expert care more accessible, especially in underserved areas.

KEY MARKET STATISTICS
Base Year [2023] USD 6.47 billion
Estimated Year [2024] USD 6.94 billion
Forecast Year [2030] USD 10.87 billion
CAGR (%) 7.67%

Regional Insights

In the Americas region, particularly the United States and Canada, basal cell carcinoma treatment is a highly advanced market driven by a robust healthcare infrastructure and significant investments in cancer research. Consumers in these regions benefit from early screening programs, which contribute to high awareness levels and early diagnosis. Patients prefer innovative treatments such as targeted therapies and advanced non-invasive technologies. Insurance coverage hugely impacts customer purchasing behavior, with most opting for treatments approved by health authorities. In the European Union, healthcare systems provide extensive coverage, influencing treatment accessibility and consumer purchasing decisions. There is a strong emphasis on cost-efficiency and evidence-based treatments. Recent EU-wide initiatives have aimed to harmonize cancer treatment protocols, increasing the accessibility of high-quality treatment options. Stringent regulations pertaining to the approval, safety, and efficacy of BCC treatments create a standardized framework and lead to the development of highly advanced and safe therapies. The APAC region presents an evolving landscape for the BCC treatment market, owing to growing awareness about skin cancers and government support for extending access to healthcare solutions. China, Japan, India, South Korea, Singapore, and Australia Japan offer significant investments in oncology research and healthcare infrastructure, emphasizing developing cost-effective treatment solutions. Digital health initiatives and the proliferation of telemedicine have played a key role in improving access to BCC treatment.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Basal Cell Carcinoma Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Prevalence of basal cell carcinoma worldwide
      • Growing awareness regarding early diagnosis and treatment of skin cancer globally
    • Market Restraints
      • High cost of basal cell carcinoma treatment
    • Market Opportunities
      • Advancements and improvements in BCC treatment
      • Emerging trend of telemedicine and teledermatology
    • Market Challenges
      • Concerns associated with stringent regulatory approval
  • Market Segmentation Analysis
    • Treatment Type: High effectiveness of drug therapies and surgery interventions in escalating the BCC completely
    • Route of Administration: Rapid effect provided by parenteral administration leading to its preference for managing severe BCC cases
    • Clinical Variant: Focused efforts to improve and provide advanced treatments for sclerosing and superficial spreading BCC to manage its aggressive nature
    • End-Users: Government support for expanding and modernizing hospital and clinic facilities
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Basal Cell Carcinoma Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Basal Cell Carcinoma Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Elekta Unveils Evo, a Groundbreaking Adaptive CT-Linac for Enhanced Cancer Treatment

Elekta, a global company in precision radiation therapy solutions, unveiled its Evo CT-linac, offline and online adaptive radiation therapy, enhancing the precision of image-guided treatments. This state-of-the-art system combines high-definition AI-assisted imaging with versatile radiation therapy modalities, catering to individualized patient care. [Published On: 2024-05-03]

Medicus Pharma Ltd. Advances Basal Cell Carcinoma Treatment Through Strategic Acquisitions and Enhanced Regulatory Strategies

Medicus Pharma Ltd., a biotech holding company, made significant strides in advancing therapies for basal cell carcinoma (BCC), following its acquisition of SkinJect, Inc. SkinJect, a Medicus subsidiary, holds an exclusive license for a revolutionary Dissolvable Microneedle Array drug delivery system. Over the past six months, Medicus Pharma Ltd. has expedited the FDA regulatory approval process for the SkinJect transdermal patch designed to treat BCC. [Published On: 2024-04-25]

Innovative Advances in Non-Invasive Basal Cell Carcinoma Treatment by Medicus Pharma Ltd., Update on Regulatory Development and Clinical Studies

Medicus Pharma Ltd. has received feedback from the U.S. Food and Drug Administration (FDA) regarding their new treatment method for basal cell carcinoma (BCC), which involves the use of micro-array needles containing doxorubicin (D-MNA). The company planned to boost clinical trials as a significant step toward establishing a ground-breaking, non-invasive treatment option for BCC. [Published On: 2024-03-31]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Basal Cell Carcinoma Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Basal Cell Carcinoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Almirall, LLC, Amgen Inc., Bausch Health Companies Inc., Biofrontera AG, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Galderma S.A., Glenmark Pharmaceuticals Limited, LEO Pharma A/S, Medicus Pharma Ltd., Medivir AB, OncoBeta GmbH, Perrigo Company PLC, Redx Pharma PLC, Regeneron Pharmaceuticals, Inc., Sanofi S.A., SkinCure Oncology, Sol-Gel Technologies Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Basal Cell Carcinoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Drug Therapy
      • Immunotherapy
      • Oral Medications
      • Targeted Therapy
      • Topical Medications
    • Radiation Therapy
    • Surgery
  • Route of Administration
    • Oral
    • Parenteral
  • Clinical Variant
    • Nodular Basal Cell Carcinoma
    • Pigmented Basal Cell Carcinoma
    • Sclerosing Basal Cell Carcinoma
    • Superficial Spreading Basal Cell Carcinoma
  • End-Users
    • Homecare
    • Hospitals & Clinics
    • Specialty Centres
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Illinois
        • Massachusetts
        • New Jersey
        • New York
        • North Carolina
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of basal cell carcinoma worldwide
      • 5.1.1.2. Growing awareness regarding early diagnosis and treatment of skin cancer globally
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of basal cell carcinoma treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and improvements in BCC treatment
      • 5.1.3.2. Emerging trend of telemedicine and teledermatology
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with stringent regulatory approval
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: High effectiveness of drug therapies and surgery interventions in escalating the BCC completely
    • 5.2.2. Route of Administration: Rapid effect provided by parenteral administration leading to its preference for managing severe BCC cases
    • 5.2.3. Clinical Variant: Focused efforts to improve and provide advanced treatments for sclerosing and superficial spreading BCC to manage its aggressive nature
    • 5.2.4. End-Users: Government support for expanding and modernizing hospital and clinic facilities
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Basal Cell Carcinoma Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Drug Therapy
  • 6.3. Radiation Therapy
  • 6.4. Surgery

7. Basal Cell Carcinoma Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Basal Cell Carcinoma Treatment Market, by Clinical Variant

  • 8.1. Introduction
  • 8.2. Nodular Basal Cell Carcinoma
  • 8.3. Pigmented Basal Cell Carcinoma
  • 8.4. Sclerosing Basal Cell Carcinoma
  • 8.5. Superficial Spreading Basal Cell Carcinoma

9. Basal Cell Carcinoma Treatment Market, by End-Users

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals & Clinics
  • 9.4. Specialty Centres

10. Americas Basal Cell Carcinoma Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Basal Cell Carcinoma Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Basal Cell Carcinoma Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Elekta Unveils Evo, a Groundbreaking Adaptive CT-Linac for Enhanced Cancer Treatment
    • 13.3.2. Medicus Pharma Ltd. Advances Basal Cell Carcinoma Treatment Through Strategic Acquisitions and Enhanced Regulatory Strategies
    • 13.3.3. Innovative Advances in Non-Invasive Basal Cell Carcinoma Treatment by Medicus Pharma Ltd., Update on Regulatory Development and Clinical Studies
    • 13.3.4. Groundbreaking FDA-Cleared Device Enhances Early Detection of Skin Cancer in Primary Care Settings
    • 13.3.5. Final Enrollment and Dosing in Phase 2 Trial of a Non-Surgical Treatment VP-315 for Basal Cell Carcinoma
    • 13.3.6. Strategic Collaboration Between Medison Pharma and Regeneron to Enhance Global Access to Libtayo for Cancer Treatment
    • 13.3.7. Strategic Collaboration between AbbVie and Umoja Biopharma to Advance Oncology Treatment with Innovative Chimeric Antigen Receptor (CAR) T-cell Therapies
    • 13.3.8. Innovative Phase 2 Clinical Study by Medicus Pharma Targets Non-Invasive Treatment for Basal Cell Carcinoma
    • 13.3.9. Bristol Myers Squibb Enhances Oncology Portfolio Through Strategic Acquisitions
    • 13.3.10. EU Approval of Libtayo for Advanced Lung Cancer Broadens Treatment Horizons
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Bausch Health Companies Inc.
    • 13.4.2. Bristol-Myers Squibb Company
    • 13.4.3. Regeneron Pharmaceuticals, Inc.
    • 13.4.4. F. Hoffmann-La Roche AG
    • 13.4.5. Sun Pharmaceutical Industries Ltd.

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BASAL CELL CARCINOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BASAL CELL CARCINOMA TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. BASAL CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. BASAL CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BASAL CELL CARCINOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TOPICAL MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TOPICAL MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY NODULAR BASAL CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY NODULAR BASAL CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PIGMENTED BASAL CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PIGMENTED BASAL CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SCLEROSING BASAL CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SCLEROSING BASAL CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SUPERFICIAL SPREADING BASAL CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SUPERFICIAL SPREADING BASAL CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CENTRES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CENTRES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 297. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 307. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, B